Safety and tolerability of tedizolid as oral treatment for bone and joint infections

By sjmartinez • September 27, 2023

Miller LG, Flores EA, Launer B, Lee P, Kalkat P, Derrah K, Agrawal S, Schwartz M, Steele G, Kim T, Kuvhenguhwa MS. Safety and tolerability of tedizolid as oral treatment for bone and joint infections. Microbiol Spectr. 2023 Sep 26:e0128223. doi: 10.1128/spectrum.01282-23. Epub ahead of print. PMID: 37750695.

Tags: bone and joint infection, Gram-positive bacteria, Infectious Diseases, Publications, tedizolid

High affinity CD16 polymorphism associated with reduced risk of severe COVID-19

Qualls AE, Tsao T, Lui I, Lim SA, Su Y, Chen E, Duchen D, Maecker HT, Kim-Schulze S, Montgomery RR, Krammer F, Langelier CR, Levy[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]

Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV

Zheng Y, Currier JS, Hughes MD. Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial[...]